Components:
Calcium Acetate
Calcium Acetate
Method of action:
Mineral, Mineral Supplements
Mineral, Mineral Supplements
Available in countries
See all
close

Name of the medicinal product

A Kalcijs D3

Qualitative and quantitative composition

Calcium Acetate

Therapeutic indications

The information provided in Therapeutic indications of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Correction of hyperphosphataemia associated with chronic renal failure in patients undergoing dialysis.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

For oral use

Initially one tablet 3 times a day. The tablet should be swallowed whole with a meal to achieve the maximal phosphate binding effect. Where the patient cannot swallow the tablets whole they may be broken and taken with food. Tablets, whether whole or broken, should not be chewed due to their bitter taste. The dose can be increased until the desired serum phosphate level is achieved, as long as hypercalcaemia does not occur. Most patients need 4 to 6 tablets per day (1 to 2 tablets with each meal).

The maximum recommended daily dose is 12 tablets.

Contraindications

The information provided in Contraindications of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Hypersensitivity to the active substance or to any of the excipients.

Hypercalcaemia.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

The use of phosphate binders in renal failure should be in conjunction with dietary advice regarding phosphate intake and methods of dialysis appropriate to the patient.

The dose will need to be adjusted depending on phosphate intake or removal by dialysis and on the ensuing effect on serum calcium. This requires regular monitoring, for example weekly, of both the serum phosphate and calcium levels to determine efficacy and prevent hypercalcaemia.

If hypercalcaemia occurs, the dosage should be reduced or the treatment withdrawn temporarily, depending on the degree of hypercalcaemia. The risk of hypercalcaemia needs to be considered particularly during concomitant treatment with Vitamin D preparations.

The concomitant administration of calcium and vitamin D derivatives is to be made under the supervision of a physician.

Patients suffering with progressive renal failure may exhibit signs of, and should be warned of the symptoms of, hypercalcaemia, ectopic or vascular calcification, or adynamic bone disease. Regular monitoring is required since caution is needed in administering A Kalcijs D3 under these circumstances.

The long-term toxicity of A Kalcijs D3 has not been evaluated in clinical trials. In particular during long-term phosphate binding therapy with calcium salts there have been reports of tissue calcifications. It is not known whether the risk of calcification is higher with A Kalcijs D3 than with other calcium salts.

Patients should be advised to seek medical advice before taking non-prescription antacids containing calcium carbonate or other calcium salts to avoid adding to the calcium load.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No effects on the ability to drive and use machines have been observed.

Undesirable effects

The information provided in Undesirable effects of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Uncommon (0.1% - 1%) Undesirable effects are nausea, vomiting, diarrhoea and constipation.

Hypercalcaemia can occur and the serum levels of total and ionised calcium should be monitored. Mild hypercalcaemia (Ca >2.6 mmol/L) may occur in about 1% of patients and may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcaemia (Ca >3.0 mmol/L) may occur in about 0.1% of patients and can be associated with confusion, delirium, stupor and in very severe cases coma. Patients should be advised to consult their doctor if any of these symptoms occur.

Overdose

The information provided in Overdose of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Overdose with calcium substances may lead to soft tissue calcifications.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Pharmacotherapeutic group: Drugs for treatment of hyperkalaemia and hyperphosphataemia

ATC code: V03A E

Phosphate binder.

Calcium ions of calcium acetate interact with and bind to phosphates in the gastro-intestinal tract to form calcium phosphate an insoluble or partially soluble product, which is excreted in the faeces.

Both components of A Kalcijs D3, calcium and acetate, are normal physiological components of the body and are also present in food. As a naturally occurring food constituent, calcium acetate is generally regarded as safe. However, excessive intake of calcium salts can result in hypercalcaemia.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Calcium acetate is not indicated for systemic availability. The residual acetate will be metabolised through bicarbonate, which will be further excreted via normal metabolic routes.

The amount of calcium not involved in the binding of phosphate is variable and any unbound calcium may be absorbed. Therefore regular monitoring of calcium levels is recommended.

Pharmacotherapeutic group

The information provided in Pharmacotherapeutic group of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close
Drugs for treatment of hyperkalaemia and hyperphosphataemia

Preclinical safety data

The information provided in Preclinical safety data of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No specific studies are available on A Kalcijs D3 calcium acetate tablets.

Incompatibilities

The information provided in Incompatibilities of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable.

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No special requirements.

Name of the medicinal product
A Kalcijs D3
Qualitative and quantitative composition
Calcium Acetate
Therapeutic indications
The information provided in Therapeutic indications of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Correction of hyperphosphataemia associated with chronic renal failure in patients undergoing dialysis.

Dosage (Posology) and method of administration
The information provided in Dosage (Posology) and method of administration of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

For oral use

Initially one tablet 3 times a day. The tablet should be swallowed whole with a meal to achieve the maximal phosphate binding effect. Where the patient cannot swallow the tablets whole they may be broken and taken with food. Tablets, whether whole or broken, should not be chewed due to their bitter taste. The dose can be increased until the desired serum phosphate level is achieved, as long as hypercalcaemia does not occur. Most patients need 4 to 6 tablets per day (1 to 2 tablets with each meal).

The maximum recommended daily dose is 12 tablets.

Contraindications
The information provided in Contraindications of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Hypersensitivity to the active substance or to any of the excipients.

Hypercalcaemia.

Special warnings and precautions for use
The information provided in Special warnings and precautions for use of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

The use of phosphate binders in renal failure should be in conjunction with dietary advice regarding phosphate intake and methods of dialysis appropriate to the patient.

The dose will need to be adjusted depending on phosphate intake or removal by dialysis and on the ensuing effect on serum calcium. This requires regular monitoring, for example weekly, of both the serum phosphate and calcium levels to determine efficacy and prevent hypercalcaemia.

If hypercalcaemia occurs, the dosage should be reduced or the treatment withdrawn temporarily, depending on the degree of hypercalcaemia. The risk of hypercalcaemia needs to be considered particularly during concomitant treatment with Vitamin D preparations.

The concomitant administration of calcium and vitamin D derivatives is to be made under the supervision of a physician.

Patients suffering with progressive renal failure may exhibit signs of, and should be warned of the symptoms of, hypercalcaemia, ectopic or vascular calcification, or adynamic bone disease. Regular monitoring is required since caution is needed in administering A Kalcijs D3 under these circumstances.

The long-term toxicity of A Kalcijs D3 has not been evaluated in clinical trials. In particular during long-term phosphate binding therapy with calcium salts there have been reports of tissue calcifications. It is not known whether the risk of calcification is higher with A Kalcijs D3 than with other calcium salts.

Patients should be advised to seek medical advice before taking non-prescription antacids containing calcium carbonate or other calcium salts to avoid adding to the calcium load.

Effects on ability to drive and use machines
The information provided in Effects on ability to drive and use machines of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No effects on the ability to drive and use machines have been observed.

Undesirable effects
The information provided in Undesirable effects of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Uncommon (0.1% - 1%) Undesirable effects are nausea, vomiting, diarrhoea and constipation.

Hypercalcaemia can occur and the serum levels of total and ionised calcium should be monitored. Mild hypercalcaemia (Ca >2.6 mmol/L) may occur in about 1% of patients and may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcaemia (Ca >3.0 mmol/L) may occur in about 0.1% of patients and can be associated with confusion, delirium, stupor and in very severe cases coma. Patients should be advised to consult their doctor if any of these symptoms occur.

Overdose
The information provided in Overdose of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Overdose with calcium substances may lead to soft tissue calcifications.

Pharmacodynamic properties
The information provided in Pharmacodynamic properties of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Pharmacotherapeutic group: Drugs for treatment of hyperkalaemia and hyperphosphataemia

ATC code: V03A E

Phosphate binder.

Calcium ions of calcium acetate interact with and bind to phosphates in the gastro-intestinal tract to form calcium phosphate an insoluble or partially soluble product, which is excreted in the faeces.

Both components of A Kalcijs D3, calcium and acetate, are normal physiological components of the body and are also present in food. As a naturally occurring food constituent, calcium acetate is generally regarded as safe. However, excessive intake of calcium salts can result in hypercalcaemia.

Pharmacokinetic properties
The information provided in Pharmacokinetic properties of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Calcium acetate is not indicated for systemic availability. The residual acetate will be metabolised through bicarbonate, which will be further excreted via normal metabolic routes.

The amount of calcium not involved in the binding of phosphate is variable and any unbound calcium may be absorbed. Therefore regular monitoring of calcium levels is recommended.

Pharmacotherapeutic group
The information provided in Pharmacotherapeutic group of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close
Drugs for treatment of hyperkalaemia and hyperphosphataemia
Preclinical safety data
The information provided in Preclinical safety data of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No specific studies are available on A Kalcijs D3 calcium acetate tablets.

Incompatibilities
The information provided in Incompatibilities of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable.

Special precautions for disposal and other handling
The information provided in Special precautions for disposal and other handling of A Kalcijs D3 is based on data of another medicine with exactly the same composition as the A Kalcijs D3 of the medicine (Calcium Acetate). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug A Kalcijs D3 directly from the package or from the pharmacist at the pharmacy.
more... close

No special requirements.

Available in countries
See all
close